Literature DB >> 18436844

In vivo toxicity study of rhodamine 6G in the rat retina.

Sebastian Thaler1, Christos Haritoglou, Tomasz J Choragiewicz, Andre Messias, Aneta Baryluk, C Albrecht May, Robert Rejdak, Michal Fiedorowicz, Eberhart Zrenner, Frank Schuettauf.   

Abstract

PURPOSE: To investigate the intraocular effect of rhodamine 6G (R6G) on retinal structures and function in an in vivo rat model and to develop an in vivo method for accurate evaluation of new dyes for intraocular surgery.
METHODS: R6G in physiologic saline solution (PSS) was injected into the vitreous of adult Brown Norway rats at concentrations of 0.0002%, 0.002%, 0.02%, 0.2%, and 0.5%. Control animals received only PSS. Retinal toxicity was assessed by retinal ganglion cell (RGC) counts, light microscopy 7 days later, photopic electroretinography (ERG), and measurement of scotopic sensitivity and recovery of dark adaptation 48 hours and 7 days after intravitreous injection.
RESULTS: R6G at concentrations of 0.2% and 0.5% led to a dose-dependent loss of RGC. The most significant loss occurred at 0.5%. Lower concentrations (0.0002%, 0.002%, and 0.02%) produced no statistically significant retinal ganglion cell loss. Analysis of the eyes by light microscopy showed no structural changes in the central retina, although injections of 0.5% R6G were followed by impressive degenerative changes adjacent to the injection sites. ERGs showed no effects of the highest R6G concentration on rods, kinetics of rhodopsin recovery after bleaching, or cone-driven responses.
CONCLUSIONS: R6G can be safely injected in doses of up to 0.02% in rats, but has a toxic effect on retinal ganglion cells at higher concentrations. Accumulation of R6G may be a problem at higher concentrations, particularly at the injection site.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436844     DOI: 10.1167/iovs.07-1476

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Comparison and mechanism of photocatalytic activities of N-ZnO and N-ZrO2 for the degradation of rhodamine 6G.

Authors:  Hanggara Sudrajat; Sandhya Babel
Journal:  Environ Sci Pollut Res Int       Date:  2016-02-13       Impact factor: 4.223

2.  In vivo biocompatibility of a new cyanine dye for ILM peeling.

Authors:  S Thaler; C Haritoglou; F Schuettauf; T Choragiewicz; C A May; F Gekeler; M D Fischer; H Langhals; A Schatz
Journal:  Eye (Lond)       Date:  2014-12-19       Impact factor: 3.775

3.  Tempol protects against intravitreous indocyanine green-induced retinal damage in rats.

Authors:  Sebastian Thaler; Bogomil Voykov; Gabriel Willmann; Michal Fiedorowicz; Robert Rejdak; Florian Gekeler; C Albrecht May; Andreas Schatz; Frank Schuettauf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-31       Impact factor: 3.117

Review 4.  [Biocompatibility of dyes for vitreoretinal surgery].

Authors:  S Thaler; F Schüttauf; C Haritoglou
Journal:  Ophthalmologe       Date:  2009-01       Impact factor: 1.059

Review 5.  Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.

Authors:  Hemant Sarin
Journal:  J Transl Med       Date:  2009-09-01       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.